Adherence to disease-modifying therapies (DMTs) was associated with slower MS disability progression and less healthcare resource utilization (HCRU), according to a study published in Multiple Sclerosis and Related Disorders. Lilyana Amezcua, MD, and colleagues examined data from 2011 to 2017, assessing adherence based on the proportion of days covered with DMTs. They compared outcomes between adherent and non-adherent cohorts, including time to relapse, relapse rate, time to use of assistive devices, and annual HCRU. Adherent individuals had a longer time to first relapse (P<0.0001) and a lower annualized relapse rate (P<0.0001), as well as longer time to cane/walker use (P=0.0067) and wheelchair use (P=0.0002) compared with non-adherent individuals. Adherent individuals also had fewer annual inpatient and ED visits and lower total costs (P<0.0001). Differences were generally more pronounced between matched adherent and highly non-adherent pairs compared with matched adherent and moderately non-adherent pairs, according to the study results.
Create Post
Twitter/X Preview
Logout